A Phase 3 interventional study of Aflibercept and Placebo (for aflibercept) in Prostatic Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 31 sites in 31 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-22.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Prostatic Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Sanofi.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one has the largest enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 3, and was the 14th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 34 studies in Prostatic Neoplasms by Sanofi is open now. The open studies under Prostatic Neoplasms, anywhere →
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 10 · Phase 4 5
First in 2001; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,224 is above the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 31 interventional studies, 131 across the 2 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Prostatic Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).
The secondary objectives were:
The study consisted in 3-week treatment cycles until progressive disease, unacceptable toxicity, or participant's refusal of further study treatment. After disease progression, participants were to be followed every 3 months until death or the study cutoff date, whichever came first.
The study cut-off date was event-driven and was defined as the date when 873 deaths had occurred.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
Drug: Placebo (for aflibercept) · Drug: Docetaxel · Drug: Prednisone or Prednisolone
Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
Drug: Aflibercept · Drug: Docetaxel · Drug: Prednisone or Prednisolone
25 mg/ml solution 6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle
Also known as: AVE0005, ZALTRAP®)
Sterile aqueous buffered solution identical to aflibercept 1-hour IV on Day 1 of each 3-Week cycle
Marketed formulation 75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
Also known as: Taxotere®
Drug pages: Prednisone · Prednisolone
Marketed formulation 5 mg twice daily PO from day 1 continuously
Overall Survival Time
Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause. The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.
Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)
Prostate Specific Antigen Response Rate
Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.
Time frame: Before randomization (baseline) then every 3 weeks up to PSA progression (≥25% increase) or the cut-off date, whichever occurred first
Time to Skeletal Related Events
Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain. Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first. The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.
Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)
Progression Free Survival Time
Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE). Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first. The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.
Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)
Tumor Response Rate in Participants With Measurable Disease
Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.
Time frame: Before randomization (baseline) then every 3 months up to tumor progression (≥25% increase) or the cut-off date, whichever occurred first
Prostate Specific Antigen Progression-free Survival Time
Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response. PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first. The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.
Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)
Pain Progression-free Survival Time
Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores. Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first. The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.
Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)
Pain Response Rate
Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.
Time frame: Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life
Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns. FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.
Time frame: Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first
Number of Participants With Adverse Events as a Measure of Safety
Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study. AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).
Time frame: From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days
Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept
Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab). A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.
Time frame: Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug
Between August 2007 and February 2010, a total of 1548 patients gave informed consent for this study.
| Milestone | Placebo | Aflibercept |
|---|---|---|
| Started | 612 | 612 |
| Treated | 604 | 605 |
| Still treated at cut-off date | 1 | 2 |
| Completed | 0 | 0 |
| Not completed | 612 | 612 |
| Withdrew: Adverse event | 127 | 266 |
| Withdrew: Disease progression | 334 | 186 |
| Withdrew: Physician decision | 75 | 47 |
| Withdrew: Participant's request | 53 | 84 |
| Withdrew: Consent withdrawn | 4 | 5 |
| Withdrew: Poor compliance to protocol | 5 | 7 |
| Withdrew: Reason unspecified | 5 | 8 |
| Withdrew: Not treated | 8 | 7 |
| Withdrew: Treatment ongoing | 1 | 2 |
Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause. The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.
| months | Placebo | Aflibercept |
|---|---|---|
| Overall Survival Time | 21.22 (19.614 to 23.754) | 22.14 (20.304 to 24.082) |
Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.
| percentage of participants | Placebo | Aflibercept |
|---|---|---|
| Prostate Specific Antigen Response Rate | 63.5 (59.5 to 67.5) | 68.6 (64.7 to 72.4) |
Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain. Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first. The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.
| months | Placebo | Aflibercept |
|---|---|---|
| Time to Skeletal Related Events | 14.98 (13.733 to 16.427) | 15.31 (14.127 to 16.657) |
Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE). Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first. The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.
| months | Placebo | Aflibercept |
|---|---|---|
| Progression Free Survival Time | 6.24 (5.585 to 6.899) | 6.90 (6.209 to 7.359) |
Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.
| percentage of participants | Placebo | Aflibercept |
|---|---|---|
| Tumor Response Rate in Participants With Measurable Disease | 28.1 (23.2 to 33.1) | 38.7 (33.4 to 44.0) |
Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response. PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first. The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.
| months | Placebo | Aflibercept |
|---|---|---|
| Prostate Specific Antigen Progression-free Survival Time | 8.11 (7.622 to 8.575) | 8.25 (7.819 to 8.772) |
Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores. Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first. The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.
| months | Placebo | Aflibercept |
|---|---|---|
| Pain Progression-free Survival Time | 9.72 (8.509 to 11.499) | 9.20 (8.181 to 10.448) |
Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.
| percentage of participants | Placebo | Aflibercept |
|---|---|---|
| Pain Response Rate | 46.3 (34.3 to 58.2) | 35.8 (24.3 to 47.3) |
Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns. FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.
| units on a scale | Placebo | Aflibercept |
|---|---|---|
| Change from baseline at cycle 1 (n =493, 461) | 5.08 ± 12.73 | 1.30 ± 15.70 |
| Change from baseline at cycle 2 (n =467, 437) | 6.22 ± 14.50 | -0.03 ± 17.99 |
| Change from baseline at cycle 6 (n =293, 224) | 5.50 ± 16.38 | -1.00 ± 16.85 |
| Change from baseline at cycle 10 (n =158, 117) | 6.61 ± 16.35 | -1.60 ± 15.41 |
Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study. AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).
| participants | Placebo | Aflibercept |
|---|---|---|
| Any Adverse Event | 585 | 607 |
| - Grade 3-4 AE | 290 | 470 |
| - Serious AE | 184 | 331 |
| - AE leading to death | 23 | 46 |
| --- Related AE leading to death | 8 | 19 |
| - AE leading to permanent discontinuation | 125 | 268 |
| - AE leading to premature discontinuation | 73 | 116 |
Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab). A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.
| participants | Placebo | Aflibercept |
|---|---|---|
| At baseline | 0 | 2 |
| At any time post-baseline | 4 | 9 |
| - Neutralizing Ab | 0 | 2 |
| - Not neutralizing Ab | 2 | 5 |
| - Neutralizing potential not evaluated | 2 | 2 |
Collected over Adverse Events (AE) were collected from signature of the informed consent form up to the last visit in the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 184/598 (30.8%) | 551/598 (92.1%) |
| Aflibercept | — | 331/611 (54.2%) | 573/611 (93.8%) |
| Event | Placebo | Aflibercept |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 21/598 | 48/611 |
| NeutropeniaBlood and lymphatic system disorders | 8/598 | 30/611 |
| Neutropenic infectionInfections and infestations | 12/598 | 22/611 |
| PneumoniaInfections and infestations | 11/598 | 21/611 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/598 | 20/611 |
| DehydrationMetabolism and nutrition disorders | 2/598 | 19/611 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 17/598 | 13/611 |
| DiarrhoeaGastrointestinal disorders | 11/598 | 17/611 |
| StomatitisGastrointestinal disorders | 1/598 | 14/611 |
| Anal abscessInfections and infestations | 0/598 | 13/611 |
| Event | Placebo | Aflibercept |
|---|---|---|
| StomatitisGastrointestinal disorders | 123/598 | 340/611 |
| AlopeciaSkin and subcutaneous tissue disorders | 268/598 | 224/611 |
| DiarrhoeaGastrointestinal disorders | 209/598 | 268/611 |
| FatigueGeneral disorders | 241/598 | 243/611 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 36/598 | 230/611 |
| HypertensionVascular disorders | 66/598 | 207/611 |
| Weight decreasedInvestigations | 51/598 | 201/611 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 55/598 | 199/611 |
| Decreased appetiteMetabolism and nutrition disorders | 110/598 | 190/611 |
| NauseaGastrointestinal disorders | 166/598 | 165/611 |
| Age, Continuous(Years) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Mean | 67.6 ± 8.0 | 67.9 ± 7.8 | 67.8 ± 7.9 |
| Age, Customized(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| <65 years | 225 | 195 | 420 |
| 65-74 years | 259 | 283 | 542 |
| ≥75 years | 128 | 134 | 262 |
| Sex/Gender, Customized(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Male | 612 | 612 | 1224 |
| Race/Ethnicity, Customized(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Caucasian/White | 552 | 560 | 1112 |
| Black | 17 | 15 | 32 |
| Asian/Oriental | 36 | 32 | 68 |
| Other | 7 | 5 | 12 |
| Region of Enrollment(Participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Western Europe | 219 | 227 | 446 |
| Eastern Europe | 131 | 132 | 263 |
| North America | 81 | 95 | 176 |
| South America | 88 | 71 | 159 |
| Other region | 93 | 87 | 180 |
| Body Surface Area (BSA)(m²) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Mean | 2.0 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.2 |
| Eastern Co-operative Group (ECOG) performance status(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| ECOG 0 | 285 | 283 | 568 |
| ECOG 1 | 299 | 303 | 602 |
| ECOG 2 | 28 | 26 | 54 |
The record gives a start of Aug 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept